The beneficial role of the young age on the likelihood of developing hyperglycemia during PAS treatment is supported by the case of the youngest patient of the current series, who showed IFG before PAS and achieved NGT after IGF-I normalization while on PAS therapy and by the finding of a significant correlation between patient’s age at PAS starting and Δ%FG during the first 12 months of PAS. This evidence concerns the gene IGF1 and Hyperglycemia.